Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix

Monday, March 19, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 19, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on SNY, SHPG, TXMD, and ZGNX which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on four major players in the Drug Manufacturers space:
Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX). Companies in the Pharmaceutical Manufacturing industry manufacture and process pharmaceutical products. They focus on the most profitable markets, where demand for treatment is high. All you have to do is sign up today for this free limited time offer by clicking the link below.



Paris, France headquartered Sanofi's shares recorded a trading volume of 2.03 million shares last Friday, which was above their three months average volume of 1.89 million shares. The stock finished the trading session 1.01% higher at $40.96. The Company's shares have gained 2.76% in the last month. The stock is trading below its 50-day moving average by 2.24%. Furthermore, shares of Sanofi, which provides therapeutic solutions, have a Relative Strength Index (RSI) of 53.22.  

On March 08th, 2018, Sanofi announced the successful completion of its acquisition of Bioverativ Inc. for $105 per share in cash. The tender offer for all of the outstanding shares of Bioverativ common stock expired as scheduled at one minute after 11:59 p.m. New York City Time on March 07th, 2018. Get the full research report on SNY for free by clicking below at:



On Friday, Dublin, Ireland headquartered Shire PLC's stock ended the session 1.27% higher at $133.45. A total volume of 1.01 million shares was traded. The Company's shares have gained 0.44% in the last month. The stock is trading 3.49% below its 50-day moving average. Moreover, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 49.77.  

On February 20th, 2018, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.

On February 27th, 2018, Shire announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted an accelerated assessment for lanadelumab (SHP643). Lanadelumab is an investigational treatment being evaluated for the prevention of angioedema attacks in patients 12 years and older with the rare, genetic disorder, hereditary angioedema. The free technical report on SHPG can be accessed at:



Boca Raton, Florida headquartered TherapeuticsMD Inc.'s stock ended the day 1.74% higher at $5.25. A total volume of 2.14 million shares was traded, which was above their three months average volume of 2.02 million shares. The Company's shares are trading 6.23% below their 200-day moving average. Additionally, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 45.72.  

On March 06th, 2018, TherapeuticsMD announced that CEO Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D. will participate in the Oppenheimer 28th Annual Healthcare Conference on March 20th, 2018, at 10:20 a.m. ET. Sign up for free on Wall St. Equities and claim the latest report on TXMD at:



Shares in Emeryville, California headquartered Zogenix Inc. recorded a trading volume of 859,814 shares, which was above their three months average volume of 591,750 shares. The stock ended Friday's session 1.41% lower at $42.05. The Company's shares have gained 7.96% in the last month, 13.65% over the previous three months, and 282.27% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.56% and 49.71%, respectively. Furthermore, shares of Zogenix, which develops and commercializes therapies for the treatment of central nervous system disorders in the US, have an RSI of 49.66.  

On March 06th, 2018, Zogenix announced its Q4 and full-year 2017 results. For Q4 2017, net loss from continuing operations was $(39.8) million, and total net loss was $(39.7) million. Due to the wind-down of Sumavel DosePro manufacturing operations, the Company recorded no revenue for the three months ended December 31st, 2017. For the full year, total revenue was $9.8 million, net loss from continuing operations was $(126.0) million, and total net loss was $(126.8) million. See the free research coverage on ZGNX at:



Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----sanofi-shire-therapeuticsmd-and-zogenix-300615753.html

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store